Clinical profile of primary biliary cirrhosis with features of autoimmune hepatitis: Importance of corticosteroid therapy

Hepatology Research

Volumn 44, Issue 9, 2014, Pages 947-955

  Yoshioka, Youko ^a   Taniai, Makiko ^a   Hashimoto, Etsuko ^a   Haruta, Ikuko ^a   Shiratori, Keiko ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Autoimmune hepatitis; Corticosteroid therapy; Gp210 antibody; Overlap syndrome; Primary biliary cirrhosis

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; CORTICOSTEROID; IMMUNOGLOBULIN G; SMOOTH MUSCLE ANTIBODY;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; AUTOIMMUNE HEPATITIS; CLINICAL FEATURE; COHORT ANALYSIS; CORTICOSTEROID THERAPY; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIMARY BILIARY CIRRHOSIS; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT RESPONSE;

EID: 84907853856     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12210     Document Type: Article

References (28)

1. Brunner G, Klinge O. [A chronic destructive non-suppurative cholangitis-like disease picture with antinuclear antibodies (immunocholangitis)]. Dtsch Med Wochenschr 1987; 112: 1454-1458.
2. Beuers U, Rust C. Overlap syndromes. Semin Liver Dis 2005; 25: 311-320.
3. Woodward J, Neuberger J. Autoimmune overlap syndromes. Hepatology 2001; 33: 994-1002.
4. Rust C, Beuers U. Overlap syndromes among autoimmune liver diseases. World J Gastroenterol 2008; 14: 3368-3373.
5. Heathcote EJ. Overlap syndromes. In: Bircher JBJ, McIntyre N, Rizzeto M, Rodès J, eds. Oxford Textbook of Clinical Hepatology, Vol 2. Oxford: Oxford University Press, 1999; 1135-1140.
6. Popper H, Schaffner F. Nonsuppurative destructive chronic cholangitis and chronic hepatitis. Prog Liver Dis 1970; 3: 336-354.
7. Geubel AP, Baggenstoss AH, Summerskill WH. Responses to treatment can differentiate chronic active liver disease with cholangitic features from the primary biliary cirrhosis syndrome. Gastroenterology 1976; 71: 444-449.
8. Boberg KM, Chapman RW, Hirschfield GM etal. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011; 54: 374-385.
9. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993; 18: 998-1005.
10. Alvarez F, Berg PA, Bianchi FB etal. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-938.
11. Hennes EM, Zeniya M, Czaja AJ etal. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48: 169-176.
12. Tanaka A, Harada K, Ebinuma H etal. Primary biliary cirrhosis - autoimmune hepatitis overlap syndrome: a rationale for corticosteroids use based on a nation-wide retrospective study in Japan. Hepatol Res 2011; 41: 877-886.
13. Neuhauser M, Bjornsson E, Treeprasertsuk S etal. Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis. Am J Gastroenterol 2010; 105: 345-353.
14. Chazouillères O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998; 28: 296-301.
15. Yamamoto K, Terada R, Okamoto R etal. A scoring system for primary biliary cirrhosis and its application for variant forms of autoimmune liver disease. J Gastroenterol 2003; 38: 52-59.
16. Bonder A, Retana A, Winston DM, Leung J, Kaplan MM. Prevalence of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol 2011; 9: 609-612.
17. Ludwig J, Czaja AJ, Dickson ER, LaRusso NF, Wiesner RH. Manifestations of nonsuppurative cholangitis in chronic hepatobiliary diseases: morphologic spectrum, clinical correlations and terminology. Liver 1984; 4: 105-116.
18. Williams JR. The Declaration of Helsinki and public health. Bull World Health Organ 2008; 86: 650-652.
19. Nakamura M, Shimizu-Yoshida Y, Takii Y etal. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. J Hepatol 2005; 42: 386-392.
20. Liver EAftSot. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51: 237-267.
21. Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998; 28: 360-365.
22. Chazouillères O, Wendum D, Serfaty L, Rosmorduc O, Poupon R. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol 2006; 44: 400-406.
23. Yokokawa J, Saito H, Kanno Y etal. Overlap of primary biliary cirrhosis and autoimmune hepatitis: characteristics, therapy, and long term outcomes. J Gastroenterol Hepatol 2010; 25: 376-382.
24. Al-Chalabi T, Portmann BC, Bernal W, McFarlane IG, Heneghan MA. Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival. Aliment Pharmacol Ther 2008; 28: 209-220.
25. Nakamura M, Kondo H, Mori T etal. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007; 45: 118-127.
26. Nakamura M, Komori A, Ito M etal. Predictive role of anti-gp210 and anticentromere antibodies in long-term outcome of primary biliary cirrhosis. Hepatol Res 2007; 37 (Suppl 3): S412-419.
27. Zhao P, Han Y. Low incidence of positive smooth muscle antibody and high incidence of isolated IgM elevation in Chinese patients with autoimmune hepatitis and primary biliary cirrhosis overlap syndrome: a retrospective study. BMC Gastroenterol 2012; 12: 1.
28. Taniai M, Hashimoto E, Noguchi S etal. Clinicopathological study of autoimmune hepatitis patients with or without hypergammaglobulinemia. Kanzo 1999; 24: 454-459 (Japanese).